• 1
    UNAIDS. 2011. 2010 Report on the global AIDS epidemic. Available at: (last accessed 3 June 2013).
  • 2
    WHO UNAIDS UNICEF. 2011. Global HIV/AIDS Response. Available at: (last accessed 3 June 2013).
  • 3
    Wittkop L, Gunthard HF, de Wolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363371.
  • 4
    Hamers RL, Wallis CL, Kityo C et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11: 750759.
  • 5
    Gupta RK, Jordan MR, Sultan BJ et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380: 12501258.
  • 6
    WHO. 2012. World Health Organization HIV drug resistance report. Available at: (last accessed 3 June 2013).
  • 7
    Castillo J, Arteaga G, Mendoza Y et al. HIV transmitted drug resistance in adult and pediatric populations in Panama. Rev Panam Salud Publica 2011; 30: 649656.
  • 8
    Ávila-Ríos S, García-Morales C, Garrido-Rodríguez D et al. National prevalence and trends of HIV transmitted drug resistance in Mexico. PLoS ONE 2012; 6: e27812.
  • 9
    Lloyd B, O'Connell RJ, Michael NL et al. Prevalence of resistance mutations in HIV-1-infected Hondurans at the beginning of the National Antiretroviral Therapy Program. AIDS Res Hum Retroviruses 2008; 24: 529535.
  • 10
    Murillo W, Paz-Bailey G, Morales S et al. Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. J Clin Virol 2010; 49: 239244.
  • 11
    Holguín A, Erazo K, Escobar G et al. Drug resistance prevalence in human immunodeficiency virus type 1 infected pediatric populations in Honduras and El Salvador during 1989–2009. Pediatr Infect Dis J 2011; 30: e82e87.
  • 12
    Murillo W, Lorenzana de Rivera I, Albert J, Guardado ME, Nieto AI, Paz-Bailey G. Prevalence of transmitted HIV-1 drug resistance among female sex workers and men who have sex with men in El Salvador, Central America. J Med Virol 2012; 84: 15141521.
  • 13
    WHO. 2010. WHO manual for HIV drug resistance testing using dried blood spot specimens. Available at: (last accessed 3 June 2013).
  • 14
    de Mulder M, Holguín Á. Dried blood spots for monitoring HIV infection in Public Health Programs in developing countries. Enferm Infecc Microbiol Clin 2013; 31: 100107.
  • 15
    Gifford RJ, Liu TF, Rhee SY et al. The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009; 25: 11971198.
  • 16
    Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4: e4724.
  • 17
    Johnson VA, Calvez V, Gunthard HF et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19: 156164.
  • 18
    Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011; 28: 27312739.
  • 19
    Martin DP, Lemey P, Lott M, Moulton V, Posada D, Lefeuvre P. RDP3: a flexible and fast computer program for analyzing recombination. Bioinformatics 2010; 26: 24622463.
  • 20
    Sierra M, Thomson MM, Posada D et al. Identification of 3 phylogenetically related HIV-1 BG intersubtype circulating recombinant forms in Cuba. J Acquir Immune Defic Syndr 2007; 45: 151160.
  • 21
    Ahumada-Ruiz S, Flores-Figueroa D, Toala-Gonzalez I, Thomson MM. Analysis of HIV-1 pol sequences from Panama: identification of phylogenetic clusters within subtype B and detection of antiretroviral drug resistance mutations. Infect Genet Evol 2009; 9: 933940.
  • 22
    Escoto-Delgadillo M, Vázquez-Valls E, Ramírez-Rodríguez M et al. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med 2005; 6: 403409.
  • 23
    Parham L, de Rivera IL, Murillo W et al. Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004. AIDS Res Hum Retroviruses 2011; 27: 10551059.
  • 24
    Ávila-Ríos S, Mejía-Villatoro CR, Garcia-Morales C et al. Prevalence and patterns of HIV transmitted drug resistance in Guatemala. Rev Panam Salud Publica 2011; 30: 641648.
  • 25
    Health Ministry of El Salvador. 2010. National STD/HIV-AIDS Programme – Encuesta centroamericana de vigilancia de comportamiento sexual y prevalencia de VIH/ITS en poblaciones vulnerables. Available at: (last accessed 3 June 2013).
  • 26
    Johnston E, Winters MA, Rhee SY, Merigan TC, Schiffer CA, Shafer RW. Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrob Agents Chemother 2004; 48: 48644868.
  • 27
    Bertagnolio S, Rodríguez-Díaz RA, Fuentes-Romero LL et al. Transmitted HIV drug resistance among drug-naive subjects recently infected with HIV in Mexico City: a World Health Organization survey to classify resistance and to field test two alternative patient enrollment methods. Clin Infect Dis 2012; 54(Suppl 4): S328S333.
  • 28
    Viani RM, Hsia K, Hubbard P et al. Prevalence of primary HIV-1 drug resistance in pregnant women and in newly diagnosed adults at Tijuana General Hospital, Baja California. Mexico Int J STD AIDS 2007; 18: 235238.